Acidifying Agents

Anticholinergics antagonize antiglaucoma agents and may increase intraocular pressure. Use of dicyclomine in patients with glaucoma is not recommended.

Concomitant use with albuterol tablets may lead to deleterious cardiovascular effects. Combined use not recommended on routine basis.

Close supervision and careful dosage adjustment required. Hyperpyrexia reported when amitriptyline given with anticholinergic agents, particularly in hot weather.

May enhance potential for renal toxicity, bronchospasm, and hypotension. Should be given concomitantly only with great caution.

May cause hypoglycemia through additive effects when dosage exceeds maximum recommended daily amount.

Concomitant use may increase the risk of bleeding. Avoid concomitant use when possible and monitor closely for bleeding.

Antianxiety agents potentiate CNS-depressant action of clonazepam.

Increased risk of serious bleeding with concomitant use of diclofenac and antiplatelet agents.

Coadministration increases the risk of bleeding.

Increased risk of bleeding; monitor patients for signs of bleeding during concomitant use.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Potential additive interaction with concomitantly used anticholinergic medications, may increase anticholinergic adverse effects. Avoid coadministration.

Potential additive interaction with concomitantly used anticholinergic medications; coadministration should be avoided as it may increase anticholinergic adverse effects.

Linezolid has potential for interaction with adrenergic agents; monitoring and caution required.

Increased risk of serotonin syndrome when co-administered with lithium.

Increased risk of serotonin syndrome when co-administered with lithium. Monitor for signs and symptoms; consider discontinuation if syndrome occurs.

Increased risk of serotonin syndrome when co-administered with lithium. Monitor for signs and symptoms, particularly during lithium initiation.

May increase methotrexate plasma concentrations and risk of severe adverse reactions. Monitor closely for methotrexate adverse reactions.

Disturbances of blood glucose including hyperglycemia and hypoglycemia reported. Carefully monitor blood glucose during co-administration.

Naproxen increases bleeding risk when used with antiplatelet agents. Monitor for signs of bleeding.

Octreotide inhibits glucagon secretion, requiring monitoring and adjustment of anti-diabetic treatment and blood glucose levels.

QT interval prolongation and ventricular arrhythmias can occur. Avoid coadministration with medicinal products known to prolong QT interval.

Concomitant use may result in tachycardia, arrhythmias, serious hypertensive response and possible stroke.

Should be used cautiously or avoided during pyridostigmine treatment due to interference with neuromuscular transmission.

Antiplatelet agents potentiate bleeding risk when combined with sumatriptan and naproxen sodium. Monitor for bleeding.

Other antiherpetic viral agents may interfere with the effectiveness of IMLYGIC.

Postmarketing reports of serotonin syndrome in patients taking tedizolid with serotonergic agents. Coadministration carries risk of serious serotonin syndrome.

Increased risk of renal toxicity when used with torsemide.

Acetazolamide may increase or decrease blood glucose levels. Consideration should be taken in patients receiving antidiabetic agents.

Acetazolamide may increase or decrease blood glucose levels; consideration should be taken in patients on antidiabetic therapy.

Concomitant topical acne therapy with abrasive agents should be used with caution due to possible cumulative irritancy effect.

Concomitant topical acne therapy with abrasive agents should be used with caution due to possible cumulative irritancy effect.

Possibility of additive effects when epinephrine is administered with other sympathomimetic agents.

Coadministration produces additive CNS depressant effects. Carefully consider pharmacology of agents to be employed.

Agents with anticholinergic properties may potentiate the anticholinergic-like side effects of amantadine.

May potentiate the anticholinergic-like side effects of amantadine hydrochloride.

Lower blood levels and efficacy of amphetamines. Dose adjustment may be needed based on clinical response.

Lower blood levels and efficacy of amphetamines. Dose adjustment may be needed based on clinical response.

Concurrent use may enhance potential for renal toxicity, bronchospasm, and hypotension. Should be given concomitantly with caution.

Concomitant administration may increase the risk of hypoglycemia.

Corticosteroids may increase blood glucose concentrations, requiring dosage adjustments of antidiabetic agents.

Antihistamine component has additive CNS depressant effects with antianxiety agents.

Antihistamines have additive effects with antianxiety agents and other CNS depressants.

Antihistamines have additive effects with antianxiety agents and other CNS depressants.

Increased risk of methemoglobinemia when concurrently exposed to antineoplastic agents.

Dosage adjustment of the antidiabetic drug may be required due to hydrochlorothiazide effects on glucose metabolism.

Symptomatic postural hypotension may occur; dose adjustment of antihypertensive drug may be required.

Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly.

Dosage adjustment of oral antidiabetic drugs may be required when used concurrently with chlorothiazide.

Dosage adjustment of oral antidiabetic agents may be required when used concurrently with chlorothiazide sodium.

Higher dosages of oral hypoglycemic agents may be required during chlorthalidone administration due to altered glucose control.

Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy, potentially reducing anticonvulsant efficacy.

Concomitant use may potentiate risk of bleeding.

Concomitant use may potentiate risk of bleeding. Inform patients of increased bleeding risk.

Immunosuppressive agents may suppress the response to the skin test.

Antianxiety agents may have additive CNS depressant effects with cyproheptadine.

Concomitant use may potentiate CNS effects of antianxiety agents.

Concomitant use may increase frequency and/or severity of anticholinergic effects (dry mouth, constipation, blurred vision) and may alter absorption of other drugs via gastrointestinal motility effects.

Concomitant use increases frequency and severity of anticholinergic effects including dry mouth, constipation, and blurred vision. May alter absorption of other drugs.

Corticosteroids may increase blood glucose concentration, requiring dosage adjustments of antidiabetic agents.

Dexamethasone may increase blood glucose concentrations, requiring dosage adjustments of antidiabetic agents.

Dexamethasone may increase blood glucose concentrations, requiring dosage adjustments of antidiabetic agents.

Dexamethasone may increase blood glucose concentrations, requiring dosage adjustments of antidiabetic agents.

Urinary acidifying agents lower blood levels and efficacy of amphetamines. Dose adjustment may be necessary.

Lower blood levels and efficacy of amphetamines. Increase dose based on clinical response.

Lower blood levels and efficacy of amphetamines. Dose adjustment based on clinical response may be needed.

Additive effects possible when epinephrine is administered with other sympathomimetic agents.

Additional reductions in blood pressure may occur when epoprostenol is administered with antihypertensive agents.

Prolonged bleeding time reported in patients taking antiplatelet agents with oral omega-3 fatty acids. Periodic monitoring of bleeding time recommended.

Dosage adjustment of oral antidiabetic drugs may be required when used concurrently with hydrochlorothiazide.

Concomitant use may exhibit additive CNS depression; dose of one or both agents should be reduced.

Corticosteroids may increase blood glucose, requiring dosage adjustments of antidiabetic agents.

Omega-3 fatty acids may prolong bleeding time. Monitor patients for bleeding when icosapent ethyl is used concomitantly with antiplatelet agents.

Omega-3 fatty acids may prolong bleeding time. Monitor patients for bleeding when used concomitantly with antiplatelet agents.

May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia; dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia; dose reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring required.

Concomitant use may increase myelosuppression; monitor neutrophil and platelet counts during combination therapy.

May interact additively with anticholinergic medications, increasing anticholinergic adverse effects. Avoid coadministration with other anticholinergic-containing drugs.

Corticosteroids may increase blood glucose concentrations; dosage adjustments may be required.

Disturbances of blood glucose including hyperglycemia and hypoglycemia have been reported. Careful monitoring of blood glucose is recommended.

Concomitant use may cause blood glucose disturbances including hyperglycemia and hypoglycemia. Careful monitoring of blood glucose is recommended.

Addition of levothyroxine may worsen glycemic control and increase antidiabetic agent requirements. Carefully monitor glycemic control when thyroid therapy is started, changed, or discontinued.

Addition of levothyroxine to antidiabetic therapy may result in increased antidiabetic agent requirements. Careful monitoring of diabetic control is recommended.

Urinary acidifying agents decrease blood levels and efficacy of amphetamines. Dose increase may be needed based on clinical response.

Urinary acidifying agents lower blood levels and efficacy of amphetamines. Dose adjustment may be needed.

Urinary acidifying agents can lower blood levels and efficacy of amphetamines. Dose may need to be increased based on clinical response.

Concomitant administration with lisinopril may cause increased blood-glucose-lowering effect with risk of hypoglycemia.

Corticosteroids may increase blood glucose concentrations, requiring dosage adjustments of antidiabetic agents.

Acidifying agents lower blood levels and efficacy of amphetamines. Dose adjustment may be needed based on clinical response.

Corticosteroids may increase blood glucose; dosage adjustments of antidiabetic agents may be required.

Increased risk of methemoglobinemia when concurrently exposed.

Corticosteroids may increase blood glucose concentration, requiring dosage adjustments of antidiabetic agents.

Corticosteroids may increase blood glucose concentrations, requiring dosage adjustments of antidiabetic agents.

Metolazone may affect glucose tolerance; dosage adjustments may be necessary.

Dosage adjustment of antidiabetic drug may be required due to hydrochlorothiazide interaction.

May affect the results of the metyrapone test. Consider withdrawing if possible before testing.

Additional adrenergic drugs may potentiate sympathetic effects of formoterol. Use with caution.

May cause disturbances in blood glucose including hyperglycemia and hypoglycemia. Carefully monitor blood glucose levels.

Moxifloxacin may cause blood glucose disturbances including hyperglycemia and hypoglycemia. Carefully monitor blood glucose during concomitant use.

Nadolol may cause hypoglycemia or hyperglycemia; adjust dosage of antidiabetic drug accordingly.

Concomitant use with naproxen increases bleeding risk. Monitor for signs of bleeding.

Enhanced antihypertensive effect when combined with olanzapine.

Enhanced antihypertensive effect may occur with concurrent use.

LYBALVI may enhance the effects of certain antihypertensive agents. Monitor blood pressure and reduce dosage of antihypertensive drug accordingly.

Patients with acromegaly and diabetes mellitus may require dose reductions of oral hypoglycemic agents after PEGVISOMANT initiation.

Addition of other antihypertensive agents to prazosin causes additive hypotensive effect; introduce cautiously and retitrate prazosin.

Addition of other antihypertensive agents to prazosin causes additive hypotensive effect. Introduce cautiously and retitrate prazosin based on clinical response.

Corticosteroids may increase blood glucose concentrations, requiring dosage adjustments of antidiabetic agents.

Corticosteroids may increase blood glucose concentrations, requiring dosage adjustments of antidiabetic medications.

Phenylephrine with bronchodilator sympathomimetic agents may cause tachycardia or other arrhythmias.

Quetiapine may enhance the effects of antihypertensive agents due to its hypotensive potential.

Quetiapine may enhance the effects of antihypertensive agents due to its potential for inducing hypotension.

Acidifying agents increase plasma salicylate levels by altering renal tubular reabsorption.

Concurrent use may potentiate the risk of bleeding.

Hypotensive effect of sodium nitroprusside is augmented by negative inotropic agents.

Hypoglycemic agents may require dose adjustment when used concomitantly with somatropin.

Dosage adjustment of the antidiabetic drug may be required.

Potentiation of the action of uricosuric agents may be noted, possibly due to displacement from albumin or pharmacodynamic mechanism.

Concomitant use not recommended; combined effect on cardiovascular system may be deleterious. Exception: aerosol bronchodilators of adrenergic-stimulant type may be used for acute bronchospasm relief.

Possible additive hypotensive effect when combined with thiothixene. Patients should be observed closely for signs of excessive hypotension.

Concomitant use may cause increased blood glucose lowering effect with greater risk of hypoglycemia.

Concomitant use may increase blood glucose lowering effect with greater risk of hypoglycemia.

Corticosteroids may increase blood glucose; dosage adjustments of antidiabetics may be required.

Corticosteroids may increase blood glucose concentrations; dosage adjustments of antidiabetic agents may be required.

Immunosuppressive agents may depress or suppress reactivity to tuberculin test; reduced reactivity may persist for 5-6 weeks after discontinuation.

Hydrochlorothiazide may increase blood glucose; dosage adjustment of antidiabetic drug may be required.

Vardenafil may add to blood pressure lowering effects of antihypertensive medications.

Vardenafil hydrochloride may add to the blood pressure lowering effects of antihypertensive agents.

Concomitant use may potentiate bleeding risk. Closely monitor for bleeding when initiating or discontinuing venlafaxine.

Concurrent use may potentiate bleeding risk. Inform patients of increased bleeding risk.

Ziprasidone may enhance the effects of antihypertensive agents due to its potential for inducing hypotension.

Ziprasidone may enhance the effects of certain antihypertensive agents due to its potential for inducing hypotension.

Ziprasidone may enhance the hypotensive effects of antihypertensive agents due to its potential for inducing hypotension.

No clinically significant interactions noted with concomitant use, though caution advised pending wider clinical experience.

No well-controlled studies have been performed on patients taking antiovulatory agents. Physician must use judgment and evaluate patients prior to initiating treatment.

Clinical studies of interactions between ribavirin inhalation solution and other antiviral agents have not been conducted.

No well-controlled studies performed; physician must evaluate patients taking antiovulatory drugs before initiating Sotradecol treatment.

No well-controlled studies have been performed on patients taking antiovulatory agents; physician judgment required before initiating treatment.

Safety of ustekinumab in combination with immunosuppressive agents has not been evaluated in plaque psoriasis trials.

Safety of ustekinumab in combination with immunosuppressive agents has not been evaluated in plaque psoriasis trials.